Immunology and inflammatory disease
3 European H2020 organizations list this as part of their work — 2 as their primary capability.
Most active in this area
- PFIZER LIMITED
Global pharmaceutical company contributing drug development expertise, clinical data, and regulatory science across 54 H2020 health research partnerships.
“Active in BIOMAP (atopic dermatitis, psoriasis), 3TR (autoimmunity and inflammation mechanisms), RTCure (rheumatoid arthritis tolerance), and COMBACTE-CDI.”
PrimaryUK54 projects - ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Amsterdam's leading academic medical center with deep H2020 expertise in immunology, cardiovascular research, infectious disease, and in silico clinical trials.
“Multiple coordinated projects including REPROGRAM (epigenetic reprogramming in atherosclerosis), SENTINEL (HIV-1 dendritic cell signaling), Inflammostrome (spondyloarthritis), and EPIMAC (epigenetic medicine for inflammation).”
PrimaryNL51 projects - CHILDREN'S HOSPITAL CORPORATION
Major US pediatric research hospital contributing clinical expertise in pain medicine, neurology, immunology, and regenerative medicine to European consortia.
“LeukoTheranostics (nanotheranostics for IBD), BEAT (germinal center dynamics and T follicular helper cells), and COAGULANT (neutrophil extracellular traps) all involve immune system research.”
US9 projects